Two minutes of quick reading
Pharma IP & Regulatory Roundup 2026: Blockbuster Patent Challenges and Landmark REBYOTA Decision
The global pharmaceutical landscape in June 2026 continues to present complex legal strategies and high-stakes patent battles. From critical Paragraph IV challenges against blockbuster drugs to a definitive U.S. District Court verdict on damages for faecal microbiota transplantation (FMT) therapy, generic and innovator companies alike face shifting operational dynamics.
Below is an analytical summary of the most impactful regulatory and intellectual property (IP) developments.
1. Day-One Paragraph IV Filings Target BMS' Blockbuster Camzyos
In a major development for the generic drug industry, the USFDA's Paragraph IV database was updated on June 9, 2026, revealing that seven generic applicants simultaneously submitted Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications targeting mavacamten capsules (2.5 mg, 5 mg, 10 mg, and 15 mg).
The NCE-1 Milestone & Market Dynamics:
The Date: The filings landed on April 28, 2026, which marks the precise New Chemical Entity (NCE)-1 milestone, the first day generic developers can legally challenge an NCE’s patents under the Hatch-Waxman Act.
Exclusivity at Stake: Because multiple generic players filed on day one, they will likely share the highly lucrative 180-day market exclusivity. This shared window typically yields up to 80% of a generic drug's lifetime revenues.
Commercial Projections: Marketed under the brand name Camzyos by Bristol Myers Squibb (BMS), the drug treats symptomatic obstructive hypertrophic cardiomyopathy (HCM). It achieved blockbuster status by reaching $1.1 billion in sales in 2025 (up from $602 million in 2024), with BMS projecting peak annual revenues of $4 billion.
The IP Battlefield:
The primary patent in question is US RE50050, a reissue patent based on the original compound patent US 9,585,883. Generic challengers are expected to heavily scrutinise early international PCT applications, such as WO 2014/205223, seeking to prove anticipation or lack of novelty by arguing that a prior family member already disclosed a sub-genus encompassing mavacamten. To succeed on an obviousness challenge, filers must defend what structural lead compound a person of ordinary skill in the art (POSA) would select. Observers note that without a breakthrough, generics may face a long wait until a settlement or patent expiration in 2036.
2. Targeting Discontinued Drugs: The Case of Meloxicam (Qmiiz ODT)
A separate, highly strategic Paragraph IV application was submitted on April 20, 2026, by a single generic filer targeting TerSera Therapeutics' Qmiiz ODT (meloxicam) orally disintegrating tablets (7.5 mg and 15 mg).
Strategic Orange Book Rules:
Discontinued status: Although TerSera discontinued marketing the nonsteroidal anti-inflammatory drug (NSAID) in 2021, causing the FDA to move it to the Orange Book’s Discontinued Drug Product List, it remains a viable target for generic ANDA filers.
The Regulatory Clearing: A Citizen Petition submitted by the regulatory consulting firm Pharmobedient Consulting on September 27, 2023, prompted the FDA to officially determine that Qmiiz ODT was not withdrawn for safety or effectiveness reasons. This legally allowed generic firms to use Qmiiz as their regulatory benchmark.
Preserving Asset Value: By litigating against the generic filer over patent US 8545879 (expiring August 2030), TerSera protects the commercial value of its out-licensing portfolio, preventing its asset value from dropping to zero.
3. Patent Damages and Ongoing Royalties: Ferring & Rebiotix v. Finch Therapeutics
On the litigation front, the U.S. District Court for the District of Delaware resolved critical post-trial motions following an August 2024 jury verdict regarding REBYOTA—a faecal microbiota transplantation (FMT) therapy used to prevent recurrent C. difficile infections (rCDI). The case involved co-plaintiffs Ferring Pharmaceuticals and its wholly owned biotech subsidiary, Rebiotix Inc., against Finch Therapeutics Group and the University of Minnesota (UMN/Finch).
Key Legal Outcomes & Judge's Discretion:
The Verdict Upheld: The court denied Ferring's motions for Judgment as a Matter of Law (JMOL) and remittitur, upholding the jury's original finding of willful infringement across three patents (US 10,251,914; US 10,675,309; and US 11,541,080). The original $25,815,061 damage award stands.
No Enhanced Damages: Despite the jury's finding that the infringement was "willful," the presiding Judge denied UMN/Finch's request for treble (multiplied) damages. The court noted that Ferring had conducted freedom-to-operate (FTO) searches and mounted a robust, zealous defence, making punitive sanctions inappropriate under the Halo and Read frameworks.
Ongoing Royalty Set: The Judge exercised judicial discretion to set the ongoing post-judgment royalty rate at 5.5% for the remaining life of the patents, matching the mathematical rate of the jury’s pre-verdict running royalty.
4. Other Notable Biopharma News
Niti Aayog Pushes for R&D Spend: A recent report by India's Niti Aayog highlighted that structural constraints, such as repeated pre-grant oppositions and vague disposal timelines, create uncertainty and delay patent grants. The agency urged pharma companies to ramp up R&D spending and strengthen industry-academia linkages to boost the commercialisation of public research.
Bayer and Iambic AI Discovery Deal: German pharmaceutical major Bayer has entered into an artificial intelligence-driven drug discovery collaboration with US biotech Iambic Therapeutics. The alliance will focus on small-molecule discovery using Iambic’s AI platforms—specifically its Enchant and NeuralPLexer technologies—to address traditionally hard-to-drug targets.
-------------xx------------------xx----------------
Thank you for reading the summary. I encourage you to read the detailed post below.
Contents
Recent Paragraph -IV filings
General information
Niti Aayog Wants Pharma Companies To Ramp Up R&D Spend
Bayer taps Iambic’s AI platform in new drug discovery collaboration
Intellectual Property
Ferring Pharmaceuticals Inc. vs. Finch Therapeutics Group
Recent Paragraph -IV filings
We monitor Paragraph IV filings with the US FDA. The latest list was updated on 09 June, and two very interesting ANDAs were included.
General information
Niti Aayog Wants Pharma Companies To Ramp Up R&D Spend
The Niti Aayog report highlighted several structural constraints that discourage innovation and long-term investment. Repeated pre-grant oppositions and unclear timelines for their disposal delay patent grants, creating uncertainty for innovators. Limited technology transfer and weak industry–academia linkages reduce the commercialisation of public research
Bayer taps Iambic’s AI platform in new drug discovery collaboration
German pharma major Bayer (BAYN: DE) has entered an artificial intelligence (AI)-driven drug discovery collaboration with US biotech Iambic Therapeutics, as large drugmakers continue to test whether AI platforms can improve early-stage research productivity.
The companies said the collaboration will focus on small-molecule discovery, with Bayer using Iambic’s AI-driven platform, including its Enchant and NeuralPLexer technologies, to identify novel drug entry points and differentiated molecules against hard-to-drug targets.
Intellectual Property
Ferring Pharmaceuticals Inc. vs. Finch Therapeutics Group
This case concerns damage calculations.
In the United States, patent litigation damages are heavily regulated by the Patent Act (35 U.S.C. § 284), which mandates that a patent owner receive compensation "adequate to compensate for the infringement, but in no event less than a reasonable royalty." When an infringing product contains multiple features beyond the patented technology, damages experts must perform an economic process called apportionment to isolate the exact value attributable to the invention.
A primary method for determining this value is the "hypothetical negotiation" framework. While a jury typically evaluates these competing financial models to award past damages, the presiding district judge retains the separate legal discretion to set an ongoing royalty rate for all future post-verdict sales. Furthermore, if a jury explicitly finds that the infringement was "wilful," the judge holds the statutory power to punish the infringer by multiplying the damage award up to three times, though this punitive enhancement is strictly reserved for egregious, bad-faith misconduct.
Summary of the Case
In this lawsuit (Ferring Pharmaceuticals Inc. and Rebiotix Inc. v. Finch Therapeutics Group, Inc. et al.), the two co-plaintiffs are Ferring Pharmaceuticals and Rebiotix Inc.
Rebiotix Inc. is a specialised biotechnology company that originally developed the faecal microbiota transplantation platform and the drug REBYOTA.
Ferring Pharmaceuticals acquired Rebiotix Inc. (in 2018), making Rebiotix a wholly owned subsidiary of Ferring.
Because Rebiotix developed the core technology and formulation, and Ferring acts as the parent commercialiser and distributor of the final FDA-approved drug, they jointly sued as co-plaintiffs to defend their commercial product from the patent claims brought by Finch and the University of Minnesota.
In this case, the U.S. District Court for the District of Delaware adjudicated critical post-trial motions following an August 2024 jury verdict. The underlying dispute concerns method and system patents for faecal microbiota transplantations (FMT) used to prevent recurrent C. difficile infections (rCDI).
The jury previously determined that Ferring Pharmaceuticals Inc. and Rebiotix Inc. (Ferring) willfully infringed claim 7 of U.S. Patent No. 10,251,914 (914 patent), claims 16 and 21 of U.S. Patent No. 10,675,309 (309 patent), and claims 2 and 9 of U.S. Patent No. 11,541,080 (080 patent) through its commercial FMT therapy, REBYOTA. The jury awarded $25,815,061 in damages, comprising a $25 million upfront payment and $815,061 in ongoing royalties, and ruled two subclaims invalid as obvious.
U.S. District Judge resolved the post-trial requests by denying Ferring's motions for Judgment as a Matter of Law (JMOL) and remittitur, denying Finch and the Regents of the University of Minnesota's (collectively, "UMN/Finch") request for enhanced damages, but granting UMN/Finch an ongoing post-judgment royalty of 5.5% alongside pre- and post-judgment interest.
Technical and Operational Background
The patented technology covers compositions and delivery platforms for stabilising and transplanting live human colon microbiota into patients suffering from rCDI. The ’914 patent describes a method for reducing pathogenic Proteobacteria by at least 10% and increasing gut diversity using a donor's extract filtered through a 0.5 mm sieve to remove rough particulate matter. The ’309 and ’080 patents (the "Borody patents") cover structural enema delivery systems engineered for secure transport, utilising flexible tubing, sealed containers, and a viable, uncultured bacterial suspension protected during long-term frozen storage by a cryoprotectant like polyethene glycol.
Key Legal Analyses and Holdings
1. Denial of Ferring's Validity and Infringement JMOLs
Ferring sought to overturn the jury verdict on multiple fronts
Written Description (§ 112): Ferring argued the ’914 patent lacked adequate taxonomic description for its genus claim of at least 6 different classes of bacteria. The court noted that the specification explicitly listed the classes and detailed exact donor screening methods. Crucially, trial evidence—including an admission by Ferring’s own expert—confirmed that 95% of healthy human guts naturally contain at least 6 of the 10 listed biological classes, proving the inventors possessed the claimed genus.
Induced and Contributory Infringement: Ferring asserted it lacked the specific intent to induce healthcare providers to satisfy the "relative abundance reduction" limitation, as the REBYOTA label does not explicitly command physicians to monitor Proteobacteria. The judge clarified that product labels inevitably leading to an infringing use constitute sufficient intent under Federal Circuit precedent. Furthermore, the court rejected the notion that a 15% patient non-response rate qualified as a "substantial noninfringing use".
Obviousness (§ 103): Ferring asserted that the prior art (Hlavka) rendered the Borody patents obvious. The court upheld the jury's non-obviousness finding, pointing to substantial trial testimony that a POSA would not routinely select polyethylene glycol for an enema therapy treating a disease defined by severe diarrhoea, because polyethylene glycol is a widely known laxative.
2. Discretionary Rejection of Enhanced Damages
Despite the jury's explicit finding that Ferring's patent infringement was wilful, the Judge denied UMN/Finch's request to multiply the damages. Applying the Halo and Read frameworks, the court emphasised that enhanced damages are a punitive sanction reserved strictly for egregious, malicious, or highly culpable behaviour. Because Ferring conducted freedom-to-operate (FTO) searches, mounted a robust defence, and successfully invalidated two structural sub-claims at trial, its conduct represented standard zealous litigation rather than bad-faith misconduct.
3. Apportionment and the Post-Judgment Ongoing Royalty Rate
The court rejected Ferring's demand for remittitur, confirming that the initial $25 million upfront jury award appropriately reflected commercial values. For future sales, UMN/Finch requested a tripled ongoing royalty of 16.5%, while Ferring argued for a maximum of 5.5%.
The Judge exercised her judicial discretion to set the ongoing post-judgment royalty rate at 5.5%. The court noted that the jury’s pre-verdict running royalty of $815,061 mathematical matched a 5.5% rate. Because the jury’s unique layout heavily front-loaded compensation via the massive $25 million lump-sum—which exceeded Ferring’s total historical sales at the time of trial—tripling the running rate post-judgment would result in an inequitable economic windfall, especially since UMN/Finch lacked a competing commercial product.
Final Post-Trial Motion Disposition
Decision here
#PharmaNews #IntellectualProperty #USFDA #ParagraphIV #Camzyos #REBYOTA #Biopharma2026
